Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clevidipine Butyrate in Hypertensive Emergency
NCT05783557Phase 3Unknown
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of clevidipine in hypertensive emergency and hypertensive urgency (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoint: Proportion of patients whose SBP fell within the target range. Status: unknown.
02
Drugs
clevidipine
03
Conditions
hypertensive emergencyhypertensive urgency
Beyond the preview
Go deeper on NCT05783557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783557.